NEJM This Week — June 5, 2025. Featuring articles on metabolic dysfunction–associated steatohepatitis, lung nodules, breast cancer, and improving birth outcomes; ...

In the open-label clinical trial reported here, BDQ4LEP (Pan African Clinical Trials Registry number, PACTR202408643515316), we assessed the bactericidal activity of bedaquiline in 30 patients ...

This article was published on June 2, 2025, and updated on June 5, 2025, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

In the months since President Donald Trump took office, the science and research community has seemingly been under attack by his administration. There have been massive cuts to research funding, ...

Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.

Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with ...

A 62-year-old woman presented with a 1-day history of chest pain on the left side that had radiated to her shoulder and back and was associated with dyspnea, diaphoresis, and lightheadedness.

Artificial intelligence startup OpenEvidence inked a multi-year content agreement with the JAMA Network to use content from 13 medical journals to inform answers on its platform.

In a double-blind, randomized, placebo-controlled trial in Zimbabwe, we assigned pregnant women to receive trimethoprim–sulfamethoxazole, at a dose of 960 mg daily, or placebo from at least 14 ...

CME activities, cases, challenges, videos, and more teaching and learning tools from the New England Journal of Medicine.

The switch from fetal γ-globin to adult β-globin is controlled by BCL11A. Genetic manipulation of BCL11A improves disease outcomes by turning γ-globin expression back on to compensate for ...